The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective ... the great work of the Scorpion team to date, along ...

Scorpion's lead drug asset, a mutant-selective PI3Kα inhibitor known as STX-478, is currently in Phase 1/2 testing for the treatment of breast cancer and other solid tumors. Under the deal ...

NEW YORK – Eli Lilly on Monday said it will acquire Scorpion Therapeutics' mutant-PI3Kα inhibitor STX-478 for up to $2.5 billion while Scorpion spins out a new entity to develop its non-PI3Kα assets.

Scorpion's current pipeline, led by STX-478, our mutant-selective PI3Kα program, consists of three internally discovered clinical product candidates and multiple discovery-stage programs.

Scorpion's current pipeline, led by STX-478, our mutant-selective PI3Kα program, consists of three internally discovered clinical product candidates and multiple discovery-stage programs. Our focus is ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor ... We look forward to leveraging the great work ...